Genistein Aglycone: A Dual Mode of Action Anti-Osteoporotic Soy Isoflavone Rebalancing Bone Turnover Towards Bone Formation

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|17|27|3007-3018

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.17, Iss.27, 2010-09, pp. : 3007-3018

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation

By Kondo K.   Suzuki Y.   Ikeda Y.   Umemura K.  

European Journal of Pharmacology, Vol. 455, Iss. 1, 2002-11 ,pp. : 53-57

Elsevier

Access to resources Recommend Favorite

Micro-CT Assessments of Potential Anti-Osteoporotic Agents

By  

Current Drug Targets, Vol. 14, Iss. 13, 2013-12 ,pp. : 1542-1551

Bentham Science Publishers

Access to resources Recommend Favorite

Statins and Bone Formation.

By  

Current Pharmaceutical Design, Vol. 7, Iss. 8, 2001-05 ,pp. : 715-736

Bentham Science Publishers

Access to resources Recommend Favorite

Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health

By Journé Fabrice   Body Jean-Jacques   Leclercq Guy   Laurent Guy  

Expert Opinion on Drug Safety, Vol. 7, Iss. 3, 2008-05 ,pp. : 241-258

Informa Healthcare

Access to resources Recommend Favorite

Pegvisomant normalises markers of bone turnover in acromegaly

By  

Inpharma, Vol. 1, Iss. 1424, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite